An independent marijuana reform legislation has been sent to the desk of the President of the United States for the first time. The "Medical Marijuana and Cannabinoid Research Expansion Act" is just one step away from historic legislation.
Just a few weeks after President Joe Biden announced a large-scale marijuana pardon and instructed a review of the drug's scheduling status, the US Senate on Wednesday approved a bipartisan marijuana research bill passed by the House of Representatives.
Senate Majority Leader Chuck Schumer has stated that he will continue to hold "productive conversations" regarding broader marijuana reform. According to Marijuana Moments, he hopes to pass these reforms before the current congressional session comes to a close.
Before the vote, Schumer stated that the bill "will eliminate red tape that impedes marijuana research and open the doors for innovative new therapies derived from marijuana." "If you are one of the millions of Americans suffering from Parkinson's, epilepsy, post-traumatic stress disorder, or any other illness, marijuana may offer promising new options for treatment.
We need to conduct research first," he said. "Unfortunately, the federal government is severely lagging behind in this area. This bill will help address this issue.
At a recent meeting, each chamber presented and advanced a number of marijuana measures. However, reform has stalled before reaching the president.
The bill was submitted in July and quickly passed in the House of Representatives, before being reviewed by the Senate, which approved the legislation unanimously.
Statement:
This article is a compilation of information obtained from third-party sources and is intended solely for industry professionals for exchange and learning purposes.
This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The translation of this article is only intended for industry research and communication purposes.
Due to limitations in the translation skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.
2FIRSTS aligns with the Chinese government's stance on all domestic, Hong Kong, Macau, Taiwan, and foreign-related issues and statements.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
